

1. Ades PA. et al., (2011). "The effect of weight loss and exercise training on flow-mediated dilatation in coronary heart disease". *Chest Journal*. 140(6):1420–1427.
2. AGREE Collaboration. Appraisal of guidelines for research & evaluation (AGREE) instrument. AGREE; 2001 [updated 2001; cited 2006 Nov]. Available at www.agreecollaboration.org.
3. Athyros VG. et al., (2010). "Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis". *Lancet*. 376: 1916–22.
4. Bösner et al., (2010). "Accuracy of symptoms and signs for coronary heart disease assessed in primary care". *British Journal of General Practice*. 246-257
5. Brinton, E.A. et al., (2008). "Can menopausal hormone therapy prevent coronary heart disease?". *Trends in Endocrinology and Metabolism*. 19(6):206-212.
6. Canberra: National Health and Medical Research Council. NHMRC levels of evidence and grades for recommendations for developers of guidelines [internet] 2009. Available at: https://www.nhmrc.gov.au/_files_nhmrc/file/guidelines/developers/nhmrc_levels_grades_evidence_120423.pdf. Accessed November 23, 2012.
7. Chen ST. et al., (2010). "The effect of dietary patterns on estimated coronary heart disease risk: results from the Dietary Approaches to Stop Hypertension (DASH) trial". *Circulation: Cardiovascular quality and outcomes*. 3(5): 484–489.
8. Deanfield JE. et al., (2010). "Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?". *European Heart Journal*. 31: 2650–2659.
9. Duff LA, Kitson AL, Seers K, Humphris D. Clinical guidelines: an introduction to their development and implementation. *J Adv Nurs* 1996, 23:887–895.
10. Fayad ZA. et al., (2011). "Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE)". *Lancet*. 378: 1547–59.
11. Gerstein HC. et al., (2010). "Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial". *Circulation*. 121:1176-1187.
12. Gurbel et al., (2009). "Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in

patients with stable coronary artery disease: the ONSET/OFFSET study". *Circulation*. 120:2577-2585.

13. Hardcastle S. et al., (2008). "A randomised controlled trial on the effectiveness of a primary health care based counselling intervention on physical activity, diet and CHD risk factors". *Patient education and counseling*. 70: 31–39.
14. "How to use the evidence: assessment and application of scientific evidence. Handbook series on preparing clinical practice guidelines" (PDF). National Health and Medical Research Council (NHMRC) 2000.
15. Jonathan Afilalo et al., (2007). "Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials". *Heart Journal*. 93:914–921.
16. Kalafati M, Bellali TH, Hatzopoulou M, Fytrou H, Koreli A, Hliopoulou A, Development of clinical guidelines. *Nosileftiki* 2007, 46:31–37.
17. Kiessling A. et al., (2011). "Case-based training of evidence-based clinical practice in primary care and decreased mortality in patients with coronary heart disease". *Annals of family medicine*. 9:211-218.
18. Koenig W. et al., (2011). "Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk $\geq 5\%$ or Framingham risk $>20\%$: post hoc analyses of the JUPITER trial requested by European health authorities". *European Heart Journal*. 32:75–83.
19. Kretsoulas C. et al., (2010). "Referrals in acute coronary events for CARDiac catheterization: The RACE CAR trial". *The Canadian journal of cardiology*. 26(8):e290-e296.
20. LaRosa JC. et al., (2010). "Comparison of 80 versus 10 mg of Atorvastatin on Occurrence of Cardiovascular Events After the First Event (from the Treating to New Targets [TNT] Trial)". *The American Journal of Cardiology*. 105:283–287.
21. Leathem CS. et al., (2009). "Identifying strategies to maximize recruitment and retention of practices and patients in a multicentre randomized controlled trial of an intervention to optimize secondary prevention for coronary heart disease in primary care". *BMC Medical Research Methodology*. 9:40.
22. Martínez-Selle's et al., (2008). "Positive non-invasive tests in the chest pain unit: importance of the clinical profile for estimating the probability of coronary artery disease". *Acute Cardiac Care*. 10: 205-208.
23. Maruthur NM. et al., (2009). "Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER Trial". *Circulation*. 119(15): 2026–2031.
24. Mulders TA. et al., (2010). "Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium

- scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study". *JACC Cardiovascular Imaging*. 5(3):252-260.
25. "NHMRC additional levels of evidence and grades for recommendations for developers of guidelines" (PDF). Australian Government. National Health and Medical Research Council. Retrieved October 15, 2012.
 26. Owen CG. et al., (2009). "Is body mass index before middle age related to coronary heart disease risk in later life? Evidence from observational studies". *International Journal of Obesity*. 33(8): 866–877.
 27. Qureshi N. et al., (2012). "Effect of Adding Systematic Family History Enquiry to Cardiovascular Disease Risk Assessment in Primary Care". *Annals of internal medicine*. 156:253-262.
 28. Ridker PM. et al., (2010). "Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk"". *Circulation. Cardiovascular quality and outcomes*. 3:447-452.
 29. Rosenson et al., (2010). "Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients". *Journal of the American College of Cardiology*. 56:1079-1088.
 30. Shea B., Hamela C., Wells G., Bouter L, Kristjansson E, Grimshaw J, Henry D, Boers M. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. *Journal of Clinical Epidemiology* 2009 Oct; 62(10):1013-20.
 31. Siegrist M. et al., (2011). "A cluster randomised school-based lifestyle intervention programme for the prevention of childhood obesity and related early cardiovascular disease (JuvenTUM 3)". *BMC Public Health*. 11:258.
 32. Sun et al., (2009). "Oral L-arginine supplementation in AMI therapy". *Clinical Cardiology*. 32, 11: 649–652. Published online in Wiley InterScience (www.interscience.wiley.com).
 33. Taylor F. et al., (2013). "Statins for the primary prevention of cardiovascular disease". *Cochrane Database of Systematic Reviews*.1-3.
 34. The BARI 2D Study Group, (2009). "A randomized trial of therapies for type 2 diabetes and coronary artery disease". *The New England Journal of Medicine*. 360(24): 2503–2515.
 35. Toh. et al., (2010). "Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial". *Annals of Internal Medicine*. 152(4): 211–217.
 36. University of Oxford, Centre for Evidence Based Medicine. RCT Critical Appraisal Sheet [2005]. Oxford: Centre for Evidence Based Medicine; [Date

- unknown]. Available at: <http://www.cebm.net/index.aspx?o=1157>. Accessed February 6, 2013.
37. University of Oxford. Centre for Evidence Based Medicine. PICO Critical Appraisal Sheet [Internet]. Oxford: Centre for Evidence Based Medicine; [Date unknown]. Available at: <http://www.cebm.net/index.aspx?o=1157>. Accessed November 22, 2012.
 38. University of Oxford, Centre for Evidence Based Medicine. CAT maker [internet]. Oxford: Centre for Evidence Based Medicine; [Date unknown]. Available at: <http://www.cebm.net/index.aspx?o=1157>. Accessed November 22, 2012.
 39. Valkeinen H. et al., (2010). "Effects of exercise training on oxygen in coronary heart disease: a systematic review and meta-analysis". *Scandinavian Journal of Medicine and Science in sports*. 20: 545–555.
 40. Warnholtz et al., (2009). "Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease". *Atherosclerosis*. 204: 216–221.
 41. Wilson et al., (2009). "Efficacy of Ranolazine in Patients With Chronic Angina". *Journal of the American College of Cardiology*. 53:1510-1516.
 42. Wolff T. et al., (2009). "Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force". *Annals of Internal Medicine*. 150:405-410.
 43. Wood DA. et al., (2008). "Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial". *Lancet*. 371: 1999–2012.
 44. Woolf S, Grol R, Hutchinson A, Eccles E, Grimshaw J. Potential benefits, limitations and harms of clinical guidelines. *BMJ* 1999, 318:527-530
 45. Λιονής Χρήστος, Κατευθυντήριες Οδηγίες για γενικούς ιατρούς και όχι μόνο: αλήθεια και μύθοι, Βήμα της Πρωτοβάθμιας Φροντίδας Υγείας. *Medical Spectrum*. Ανασκοπήσεις και εξελίξεις πρακτικού ενδιαφέροντος Μάιος-Ιούνιος 2007, Τεύχος 13:39-40.
 46. Μουντουλάκης ΘΔ. Διάγνωση και Ιατρική βασισμένη σε ενδείξεις. *Ημέρες Παθολογίας* 1998; 226-7.
 47. Παναγιωτάκος Δ.Β. Επιδημιολογία Καρδιαγγειακής νόσου στην Ελλάδα και τον κόσμο. *Iatrika chronica* 2003.
 48. Brieger D, Eagle KA, Goodman SG, Steg PG, Budaj A, White K, Montalescot G. *Chest*. 2009 Nov;136(5 Suppl):e30
 49. da Silveira AD1, Ribeiro RA, Rossini AP, Stella SF, Ritta HA, Stein R, Polanczyk CA. Association of anemia with clinical outcomes in stable coronary artery disease. *Coron Artery Dis*. 2008 Feb;19(1):21-6.

50. Balion C, Santaguida PL, Hill S, Worster A, McQueen M, Oremus M, McKelvie R, Booker L, Fagbemi J, Reichert S, Raina P. Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure. *Evid Rep Technol Assess (Full Rep)*. 2006 Sep;(142):1-147.
51. 2013 ESC guidelines on the management of stable coronary artery disease The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *European Heart Journal* (2013) 34, 2949–3003.
52. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). *European Heart Journal* (2012) 33, 2569–2619.
53. Puymirat E1, Aïssaoui N, Coste P, Dentan G, Bataille V, Drouet E, Mulak G, Carrié D, Blanchard D, Simon T, Danchin N. Comparison of efficacy and safety of a standard versus a loading dose of clopidogrel for acute myocardial infarction in patients \geq 75 years of age (from the FAST-MI registry). *Am J Cardiol*. 2011 Sep 15;108(6):755-9.
54. Everts B1, Karlson B, Abdon NJ, Herlitz J, Hedner T. A comparison of metoprolol and morphine in the treatment of chest pain in patients with suspected acute myocardial infarction--the MEMO study. *J Intern Med*. 1999 Feb;245(2):133-41.
55. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). *European Heart Journal* (2012) 33, 2569–2619
56. Cabello JB1, Burls A, Emparanza JI, Bayliss S, Quinn T. Oxygen therapy for acute myocardial infarction. *Cochrane Database Syst Rev*. 2013 Aug 21;8:CD007160.
57. De Caterina R1, Madonna R, Sourij H, Wascher T. Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. *Eur Heart J*. 2010 Jul;31(13):1557-64. doi: 10.1093/eurheartj/ehq162. Epub 2010 Jun 2.
58. Ling Y1, Li X, Gao X. Intensive versus conventional glucose control in critically ill patients: a meta-analysis of randomized controlled trials. *Eur J Intern Med*. 2012 Sep;23(6):564-74
59. Poole-Wilson PA1, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, Just H, Fox KA, Pocock SJ, Clayton TC, Motro M, Parker JD, Bourassa MG, Dart AM, Hildebrandt P, Hjalmarson A, Kragten JA, Molhoek GP, Otterstad JE, Seabra-Gomes R, Soler-Soler J, Weber S; Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. *Lancet*. 2004 Sep 4-10;364(9437):849-57.

60. Saito M1, Ueshima K, Saito M, Iwasaka T, Daida H, Kohzuki M, Makita S, Adachi H, Yokoi H, Omiya K, Mikouchi H, Yokoyama H, Goto Y. Safety of Exercise-Based Cardiac Rehabilitation and Exercise Testing for Cardiac Patients in Japan. *Circ J*. 2014 May 19.
61. Rod S. Taylor, MSc, PhD, Allan Brown, MBA, MA, Shah Ebrahim, DM, MSc, Judith Jolliffe, MSc, Hussein Noorani, MSc, Karen Rees, MSc, PhD, Becky Skidmore, MLS, James A. Stone, PhD, David R. Thompson, PhD, Neil Oldridge, PhD. Exercise-Based Rehabilitation for Patients with Coronary Heart Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials. *Am J Med*. 2004;116:682–692.
62. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. *European Heart Journal* (2012) 33, 1635–1701
63. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *European Heart Journal* (2013) 34, 3035–3087.
64. Michael Pignone, MD, MPH, FACP, Writing Group Chair; Mark J. Alberts, MD; John A. Colwell, MD, PhD, MACP; Mary Cushman, MD, MSc; Silvio E. Inzucchi, MD; Debabrata Mukherjee, MD, MS, FACC; Robert S. Rosenson, MD, FACC, FAHA, FACP; Craig D. Williams, PharmD, FNLA; Peter W. Wilson, MD; M. Sue Kirkman, MD. Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. *Circulation*. 2010 Jun 22;121(24):2694-701.
65. Keeley EC1, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. *Lancet*. 2003 Jan 4;361(9351):13-20.
66. Time Delay to Treatment and Mortality in Primary Angioplasty for Acute Myocardial Infarction Every Minute of Delay Counts. Giuseppe De Luca, MD; Harry Suryapranata, MD, PhD; Jan Paul Ottervanger, MD, PhD; Elliott M. Antman, MD. *Circulation*. 2004;109:1223-1225.
67. McNamara RL1, Herrin J, Wang Y, Curtis JP, Bradley EH, Magid DJ, Rathore SS, Nallamothu BK, Peterson ED, Blaney ME, Frederick P, Krumholz HM. Impact of delay in door-to-needle time on mortality in patients with ST-segment elevation myocardial infarction. *Am J Cardiol*. 2007 Oct 15;100(8):1227-32.
68. A clinical prediction rule for the diagnosis of coronary artery disease: validation, updating, and extension. The CAD consortium. *European Heart Journal* (2011) 32, 1316–1330.

69. Poortaghi S1, Baghernia A, Golzari SE, Safayian A, Atri SB. The effect of home-based cardiac rehabilitation program on self efficacy of patients referred to cardiac rehabilitation center. *BMC Res Notes*. 2013 Jul 23;6:287.
70. McClure T1, Haykowsky MJ, Schopflocher D, Hsu ZY, Clark AM. Home-based secondary prevention programs for patients with coronary artery disease: a meta-analysis of effects on anxiety. *J Cardiopulm Rehabil Prev*. 2013 Mar-Apr;33(2):59-67.
71. Blair J1, Corrigan H, Angus NJ, Thompson DR, Leslie S. Home versus hospital-based cardiac rehabilitation: a systematic review. *Rural Remote Health*. 2011;11(2):1532.
72. Khonsari S1, Subramanian P, Chinna K, Latif LA, Ling LW, Gholami O. Effect of a reminder system using an automated short message service on medication adherence following acute coronary syndrome. *Eur J Cardiovasc Nurs*. 2014 Feb 2.
73. Blasco A1, Carmona M, Fernández-Lozano I, Salvador CH, Pascual M, Sagredo PG, Somolinos R, Muñoz A, García-López F, Escudier JM, Mingo S, Toquero J, Moñivas V, González MA, Fragua JA, López-Rodríguez F, Monteagudo JL, Alonso-Pulpón L. Evaluation of a telemedicine service for the secondary prevention of coronary artery disease. *J Cardiopulm Rehabil Prev*. 2012 Jan-Feb;32(1):25-31.
74. Dalleck LC1, Schmidt LK, Lueker R. Cardiac rehabilitation outcomes in a conventional versus telemedicine-based programme. *J Telemed Telecare*. 2011;17(5):217-21.
75. Frosch DL1, Rincon D, Ochoa S, Mangione CM. Activating seniors to improve chronic disease care: results from a pilot intervention study. *J Am Geriatr Soc*. 2010 Aug;58(8):1496-503.
76. Community-based exercise programs as a strategy to optimize function in chronic disease: a systematic review. Desveaux L1, Beauchamp M, Goldstein R, Brooks D. *Med Care*. 2014 Mar;52(3):216-26.